167 related articles for article (PubMed ID: 11081386)
1. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide for the treatment of chronic graft-versus-host disease.
Vogelsang GB; Farmer ER; Hess AD; Altamonte V; Beschorner WE; Jabs DA; Corio RL; Levin LS; Colvin OM; Wingard JR
N Engl J Med; 1992 Apr; 326(16):1055-8. PubMed ID: 1549151
[TBL] [Abstract][Full Text] [Related]
4. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
Cole CH; Rogers PC; Pritchard S; Phillips G; Chan KW
Bone Marrow Transplant; 1994 Dec; 14(6):937-42. PubMed ID: 7711671
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide for treatment of graft-versus-host disease.
Vogelsang GB; Hess AD; Santos GW
Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
[TBL] [Abstract][Full Text] [Related]
8. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
9. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
[TBL] [Abstract][Full Text] [Related]
10. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
11. Chronic graft-versus-host disease: clinical manifestation and therapy.
Ratanatharathorn V; Ayash L; Lazarus HM; Fu J; Uberti JP
Bone Marrow Transplant; 2001 Jul; 28(2):121-9. PubMed ID: 11509929
[TBL] [Abstract][Full Text] [Related]
12. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA).
Vogelsang GB; Wolff D; Altomonte V; Farmer E; Morison WL; Corio R; Horn T
Bone Marrow Transplant; 1996 Jun; 17(6):1061-7. PubMed ID: 8807115
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
16. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma.
Lee CK; de Magalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2002 Apr; 29(7):615-20. PubMed ID: 11979313
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide responsive chronic pulmonary GVHD.
Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA
Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]